TriangleNCT02187783 · OUTCOME
Overall Response Rate (ORR) ≥ 16 Weeks. FAS
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participant
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline and ≥ 16 weeks up to approximately 36 months
What was measured
ORR was determined by local, Investigator assessment for each tumor assessment and defined as responses of CR+PR ≥ 16 weeks. FAS
Groups in this outcome
Ribociclib 600 mg
LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
| Group | Source count |
|---|---|
| Ribociclib 600 mg | 105 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ribociclib 600 mg | 3 | Not reported | 0.6 | 8.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.6
- upper Limit
- 8.1
- value
- 3
- denoms
- counts
- group Id
- OG000
- value
- 105
- units
- Participants
- description
- ORR was determined by local, Investigator assessment for each tumor assessment and defined as responses of CR+PR ≥ 16 weeks. FAS
- dispersion Type
- 95% Confidence Interval
- groups
- description
- LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
- id
- OG000
- title
- Ribociclib 600 mg
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Baseline and ≥ 16 weeks up to approximately 36 months
- title
- Overall Response Rate (ORR) ≥ 16 Weeks. FAS
- type
- PRIMARY
- unit Of Measure
- participant
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice